“adcetris” Archives

Entry Author Date Location
Seattle Genetics Sets Lymphoma Drug Price at $13,500 Per Dose 08/22/11 Seattle
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs 08/22/11 National
Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas 08/19/11 Seattle
SeaGen Passes FDA Panel, Ken Stuart’s Journey to Seattle Biomed, the Latest M&A Obsession, & More Seattle-Area Life Sciences News 07/21/11 Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent 07/18/11 National
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel 07/14/11 Seattle
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel 07/14/11 Seattle
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News 07/14/11 Seattle
Seattle Genetics’ New ‘Empowered Antibody’ Looks Clean in FDA Staff Documents 07/12/11 Seattle
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week 07/12/11 Seattle
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul 07/05/11 Seattle
Cyterix Develops New Twist on an Old Idea, With ‘Smart Bomb’ Cancer Drugs 06/22/11 San Francisco
SeaGen Promotes Dobmeier 06/17/11 Seattle
SeaGen Adds $7.7M Lease 05/13/11 Seattle
Geospiza Sells to PerkinElmer, PATH Vaccine Nabs $100M, Halosource Gets China Approval, & More Seattle-Area Life Sciences News 05/12/11 Seattle
Why Are Drugs Getting Such Weird Brand Names? 05/09/11 National
SeaGen Ends March With $456M Cash 05/05/11 Seattle
Page 2 of 2 « previous page